Justin Tam
ZW Data Action TechnologiesAbout Justin Tam
Justin Tam, age 52, is an Independent Non‑Executive Director of ZW Data Action Technologies Inc. (ticker: CNET), appointed in December 2024, and deemed independent under Nasdaq Rule 5605(a)(2) and Exchange Act Rule 10A‑3 . He holds an Honours Bachelor of Applied Sciences in Electrical Engineering from the University of Waterloo and brings 30+ years’ experience across healthcare technology, investment management, and entrepreneurship .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| FINESSE Healthcare (FINESSE GROUP) | Business Development Director | Jan 2023 – Present | Focused on homecare AI; business development leadership |
| MYDOC Health Limited | General Manager | Jan 2017 – Nov 2022 | Telemedicine operations leadership; growth and execution |
| Brighten Management Limited (Family Office) | Vice President, Technology Investment | Jan 2016 – Nov 2020 | Structured/managing private equity investments in HK/Asia |
| Entrepreneur | Founder/Operator | 2002 – 2015 | Multiple ventures; cross‑market execution experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| FINESSE Healthcare | Business Development Director | Jan 2023 – Present | Homecare AI initiative under FINESSE GROUP |
| MYDOC Health Limited | General Manager | Jan 2017 – Nov 2022 | Telemedicine company established in 2015 |
| Brighten Management Limited | VP, Technology Investment | Jan 2016 – Nov 2020 | Family office PE investments across HK/Asia |
Board Governance
- Independence: The Board determined Justin Tam is “independent” under Nasdaq Rule 5605(a)(2) and Exchange Act Rule 10A‑3 .
- Committee assignments: Current committee rosters list Audit (Chang Qiu, Zhiqing Chen, Chung Wang Yiu), Compensation (Zhiqing Chen, Chang Qiu, Chung Wang Yiu), and Nominating & Corporate Governance (Zhiqing Chen, Chang Qiu, Chung Wang Yiu); Tam is not listed on any committee .
- Attendance and engagement: Board held nine meetings in 2024; no director attended fewer than 75% of Board and committee meetings; all directors attended the 2024 annual meeting (Dec 13, 2024) .
- Board leadership: CEO is also Chairman (no Lead Independent Director); independent directors plan executive sessions collaboratively without a formal lead director .
Fixed Compensation
(Director compensation – fiscal 2024)
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Total ($) |
|---|---|---|---|---|
| Justin Tam | $0 | $0 | $0 | $0 |
Notes: Grant date fair value of restricted stock is computed under FASB ASC 718; Tam’s 2024 figures reflect appointment late in 2024 .
Performance Compensation
(Director pay metrics and equity awards)
| Item | Disclosure |
|---|---|
| Performance metrics tied to director compensation | None disclosed for directors in fiscal 2024 |
| Equity award status (director) | No director options; restricted stock grants disclosed for select directors (not Tam) |
| Plan architecture | 2024 Plan in effect with 400,000 shares available as of 12/31/2024; 2025 Omnibus Equity Plan (subject to stockholder approval) reserves 500,000 shares; no awards granted yet under 2025 Plan |
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed for the last five years in the nomination table |
| Prior public company boards | None disclosed |
| Private/non‑profit/academic boards | Not disclosed |
Expertise & Qualifications
- Education: Honours BASc in Electrical Engineering, University of Waterloo .
- Sector experience: Healthcare technology, telemedicine operations, private equity investments, entrepreneurship .
- Board‑stated qualifications: “Technical acumen and business insight” contributing to innovation and value creation .
Equity Ownership
(As of record date October 9, 2025)
| Holder | Shares Beneficially Owned | Percent of Class |
|---|---|---|
| Justin Tam | None disclosed (“–”) | – |
Record date: October 9, 2025; 3,268,429 shares outstanding .
Insider Trades
| Item | Disclosure |
|---|---|
| Section 16(a) compliance (2024) | Company states all required reports were timely filed except one late Form 4 for another director (Chang Qiu); no late filings noted for Justin Tam |
| Reported Form 4 transactions for Tam | None disclosed in DEF 14A |
Governance Assessment
- Alignment and ownership: No beneficial ownership reported for Tam as of Oct 9, 2025, limiting “skin‑in‑the‑game” alignment at present .
- Committee participation: Not currently serving on Audit, Compensation, or Nominating & Corporate Governance committees; reduces direct influence on oversight levers valued by investors .
- Board independence and structure: Tam is independent, which is positive; however, combined CEO/Chair and absence of a Lead Independent Director present oversight risk and can dampen investor confidence in board effectiveness .
- Engagement: Company reports strong attendance in 2024 and directors’ participation at the annual meeting, which supports governance quality; Tam’s appointment timing suggests limited 2024 meeting exposure but attendance expectations are clear .
- Compensation practices: No director pay for Tam in 2024 (late‑year appointment); equity program capacity exists (2024 Plan; 2025 Plan pending), but no performance‑conditioned director awards disclosed; Compensation Committee did not use external consultants, which may limit benchmarking robustness .
- Policies: Insider Trading Policy in place with blackout periods; clawback provisions embedded in Omnibus Plan including Dodd‑Frank/SOX references—positive controls for pay‑for‑performance and misconduct recovery .
RED FLAGS
- Combined CEO/Chair with no Lead Independent Director (oversight concentration) .
- No beneficial ownership reported for Tam to date (weak alignment signal) .
- No committee assignments, reducing direct oversight involvement (particularly Audit/Comp) .
Potential mitigants
- Strong independence designation for Tam .
- Formal Insider Trading and clawback policies .
- Reported director attendance standards and practice .